Literature DB >> 24275132

CT screening for lung cancer: countdown to implementation.

John K Field1, David M Hansell, Stephen W Duffy, David R Baldwin.   

Abstract

Implementation of lung cancer CT screening is currently the subject of a major policy decision within the USA. Findings of the US National Lung Screening Trial showed a 20% reduction in lung cancer mortality and a 6·7% decrease in all-cause mortality; subsequently, five US professional and clinical organisations and the US Preventive Services Task Force recommended that screening should be implemented. Should national health services in Europe follow suit? The European community awaits mortality and cost-effectiveness data from the NELSON trial in 2015-16 and pooled findings of European trials. In the intervening years, a recommendation is proposed that a demonstration trial is done in the UK. In this Review, we summarise the existing evidence and identify questions that remain to be answered before the implementation of international lung cancer screening programmes.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24275132     DOI: 10.1016/S1470-2045(13)70293-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  23 in total

Review 1.  Next steps and barriers to implementing lung cancer screening with low-dose CT.

Authors:  D R Baldwin; E L O'Dowd
Journal:  Br J Radiol       Date:  2014-10-15       Impact factor: 3.039

2.  Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial.

Authors:  Arjun Nair; Natalie Gartland; Bruce Barton; Diane Jones; Leigh Clements; Nicholas J Screaton; John A Holemans; Stephen W Duffy; John K Field; David R Baldwin; David M Hansell; Anand Devaraj
Journal:  Br J Radiol       Date:  2016-07-27       Impact factor: 3.039

Review 3.  Risk assessment in relation to the detection of small pulmonary nodules.

Authors:  John K Field; Michael W Marcus; Matthijs Oudkerk
Journal:  Transl Lung Cancer Res       Date:  2017-02

4.  Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen.

Authors:  Nicola Sverzellati; M Silva; G Calareso; C Galeone; A Marchianò; S Sestini; G Sozzi; U Pastorino
Journal:  Eur Radiol       Date:  2016-02-11       Impact factor: 5.315

5.  Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma.

Authors:  Rong Qiao; Runbo Zhong; Chunlan Liu; Feifei Di; Zheng Zhang; Ling Wang; Tian Xu; Yue Wang; Liping Dai; Wanjian Gu; Baohui Han; Rongxi Yang
Journal:  Genes Genomics       Date:  2021-11-16       Impact factor: 1.839

6.  Lung cancer incidence and mortality in China, 2010.

Authors:  Rongshou Zheng; Hongmei Zeng; Siwei Zhang; Yaguang Fan; Youlin Qiao; Qinghua Zhou; Wanqing Chen
Journal:  Thorac Cancer       Date:  2014-07-03       Impact factor: 3.500

Review 7.  Chronic obstructive pulmonary disease as a risk factor for lung cancer.

Authors:  Yuichi Takiguchi; Ikuo Sekine; Shunichiro Iwasawa; Ryota Kurimoto; Koichiro Tatsumi
Journal:  World J Clin Oncol       Date:  2014-10-10

8.  Perspective: The screening imperative.

Authors:  John K Field
Journal:  Nature       Date:  2014-09-11       Impact factor: 49.962

9.  ESR/ERS white paper on lung cancer screening.

Authors:  Hans-Ulrich Kauczor; Lorenzo Bonomo; Mina Gaga; Kristiaan Nackaerts; Nir Peled; Mathias Prokop; Martine Remy-Jardin; Oyunbileg von Stackelberg; Jean-Paul Sculier
Journal:  Eur Radiol       Date:  2015-05-01       Impact factor: 5.315

10.  ESR/ERS white paper on lung cancer screening.

Authors:  Hans-Ulrich Kauczor; Lorenzo Bonomo; Mina Gaga; Kristiaan Nackaerts; Nir Peled; Mathias Prokop; Martine Remy-Jardin; Oyunbileg von Stackelberg; Jean-Paul Sculier
Journal:  Eur Respir J       Date:  2015-04-30       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.